Please use this identifier to cite or link to this item:
Title: Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.
Authors: Huurneman, Luc J
Neely, Michael
Veringa, Anette
Docobo Pérez, Fernando
Ramos-Martin, Virginia
Tissing, Wim J
Alffenaar, Jan-Willem C
Hope, William
metadata.dc.subject.mesh: Antifungal Agents
Area Under Curve
Aspergillus fumigatus
Child, Preschool
Computer Simulation
Drug Monitoring
Fungal Polysaccharides
Microbial Sensitivity Tests
Models, Statistical
Precision Medicine
Issue Date: 25-Mar-2016
Abstract: Voriconazole is the agent of choice for the treatment of invasive aspergillosis in children at least 2 years of age. The galactomannan index is a routinely used diagnostic marker for invasive aspergillosis and can be useful for following the clinical response to antifungal treatment. The aim of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) mathematical model that links the pharmacokinetics of voriconazole with the galactomannan readout in children. Twelve children receiving voriconazole for treatment of proven, probable, and possible invasive fungal infections were studied. A previously published population PK model was used as the Bayesian prior. The PK-PD model was used to estimate the average area under the concentration-time curve (AUC) in each patient and the resultant galactomannan-time profile. The relationship between the ratio of the AUC to the concentration of voriconazole that induced half maximal killing (AUC/EC50) and the terminal galactomannan level was determined. The voriconazole concentration-time and galactomannan-time profiles were both highly variable. Despite this variability, the fit of the PK-PD model was good, enabling both the pharmacokinetics and pharmacodynamics to be described in individual children. (AUC/EC50)/15.4 predicted terminal galactomannan (P= 0.003), and a ratio of >6 suggested a lower terminal galactomannan level (P= 0.07). The construction of linked PK-PD models is the first step in developing control software that enables not only individualized voriconazole dosages but also individualized concentration targets to achieve suppression of galactomannan levels in a timely and optimally precise manner. Controlling galactomannan levels is a first critical step to maximizing clinical response and survival.
metadata.dc.identifier.doi: 10.1128/AAC.03023-15
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.